Allogene Therapeutics (ALLO)
(Delayed Data from NSDQ)
$2.61 USD
+0.02 (0.77%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.60 -0.01 (-0.38%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.61 USD
+0.02 (0.77%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.60 -0.01 (-0.38%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Zacks News
Allogene (ALLO) Q4 Earnings Top Estimates, Pipeline Advances
by Zacks Equity Research
Allogene (ALLO) reports no revenues for the fourth quarter of 2020.
Allogene's (ALLO) AlloCAR T Therapy ALLO-715 IND Gets FDA Nod
by Zacks Equity Research
The FDA permits Allogene (ALLO) to initiate an early-stage study on its AlloCAR T therapy candidate, ALLO-715, in combination with SpringWorks' nirogacestat in multiple myeloma patients.
Allogene Therapeutics (ALLO) Up 8.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Allogene (ALLO) Q3 Earnings Top Estimates, Pipeline Progresses
by Zacks Equity Research
Allogene (ALLO) reports no revenues for the third quarter of 2020.
Allogene Therapeutics (ALLO) Down 9.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Allogene's (ALLO) Q2 Loss Widens Y/Y, Pipeline Progresses
by Zacks Equity Research
Allogene (ALLO) reports no revenues for the second quarter of 2020.
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ALLO) Outperforming Other Medical Stocks This Year?
Has Allogene Therapeutics (ALLO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ALLO) Outperforming Other Medical Stocks This Year?
Why Is Allogene Therapeutics (ALLO) Up 40.6% Since Last Earnings Report?
by Zacks Equity Research
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Moving Average Crossover Alert: Allogene Therapeutics
by Zacks Equity Research
Allogene Therapeutics, Inc. (ALLO) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Is Allogene Therapeutics (ALLO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ALLO) Outperforming Other Medical Stocks This Year?
Implied Volatility Surging for Allogene (ALLO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Allogene (ALLO) stock based on the movements in the options market lately.
Allogene Therapeutics (ALLO) in Focus: Stock Moves 6.6% Higher
by Zacks Equity Research
Allogene Therapeutics (ALLO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Will Allogene Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Allogene Therapeutics
How Allogene (ALLO) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Allogene (ALLO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Allogene's (ALLO) Q1 Loss Widens Y/Y, Pipeline Progresses
by Zacks Equity Research
Allogene (ALLO) reports no revenues for the first quarter of 2020.
Drug/Biotech Stock Q1 Earnings Due on May 6: ZTS, ALXN & More
by Kinjel Shah
Let us take a look at five drug/biotech companies due to release their first-quarter financial results on May 6.
5 Drug/Biotech Stocks Set to Outpace Q1 Earnings Estimates
by Kinjel Shah
Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.
Why Earnings Season Could Be Great for Allogene Therapeutics (ALLO)
by Zacks Equity Research
Allogene Therapeutics (ALLO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season
Moderna (MRNA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Progress of its pipeline candidates, especially coronavirus vaccine, is likely to have increased Moderna's (MRNA) operating expenses in the first quarter.
Is a Beat in Store for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) first-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.
What's in Store for Innoviva (INVA) This Earnings Season?
by Zacks Equity Research
Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the first quarter.
Allogene's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Allogene Therapeutics.
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ALLO) Outperforming Other Medical Stocks This Year?
Here's Why Momentum Investors Will Love Allogene Therapeutics (ALLO)
by Zacks Equity Research
Does Allogene Therapeutics (ALLO) have what it takes to be a top stock pick for momentum investors? Let's find out.